Fresenius Kabi Discusses the Prospects for the Pegfilgrastim Biosimilar
Shots:
- Fresenius Kabi discusses the US FDA’s review about the prospects of pegfilgrastim biosimilar product and the commercialization of the product
- The company also plans for MSB11456 (biosimilar, tocilizumab) based on the recent positive results which are used for the treatment of RA referencing Actemra
- The company is awaiting the completion of the US FDA’s inspection to enable the completion of the Stimufend application review. The company has scaled the pegfilgrastim biosimilars in the EU
Ref: Fresenius Kabi | Image: Fresenius Kabi
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com